海创药业10月29日获融资买入1092.18万元，融资余额3.27亿元

Group 1 - The core viewpoint of the news is that Haichuang Pharmaceutical experienced a slight decline in stock price and notable trading activity, indicating high levels of financing and margin trading [1] - On October 29, Haichuang Pharmaceutical's stock fell by 0.71%, with a trading volume of 74.88 million yuan, and a net financing outflow of 1.84 million yuan [1] - As of October 29, the total margin trading balance for Haichuang Pharmaceutical was 327 million yuan, which represents 6.57% of its circulating market value, indicating a high level of financing compared to the past year [1] Group 2 - As of June 30, the number of shareholders for Haichuang Pharmaceutical increased to 6,555, up by 56.33%, while the average circulating shares per person decreased by 28.30% to 12,435 shares [2] - For the first half of 2025, Haichuang Pharmaceutical reported a revenue of 13.17 million yuan, a significant year-on-year increase of 11,899.08%, while the net profit attributable to shareholders was -61.85 million yuan, reflecting a 38.40% increase in losses compared to the previous period [2] - Among the top ten circulating shareholders, Penghua Medical Technology Stock A ranked as the second-largest shareholder, holding 3.64 million shares, which is a decrease of 119,500 shares from the previous period [2]